TRAW — Traws Pharma Share Price
0.000.00%
Last trade - 00:00- $7.96m
- -$7.98m
- $0.23m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.33 | ||
| Price to Tang. Book | 1.33 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 35.05 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1643.56% | ||
| Return on Equity | -576.08% | ||
| Operating Margin | -62715.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.3 | -36.47% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
Directors
- James Marino NEC (71)
- Steven Fruchtman PRE (70)
- Mark Guerin CFO (52)
- Abraham Oler SVP (45)
- Mark Gelder OTH (58)
- Jerome Groopman IND (69)
- Viren Mehta IND (71)
- M. Teresa Shoemaker IND (60)
- Jack Stover IND (68)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- December 22nd, 1998
- Public Since
- July 25th, 2013
- No. of Shareholders
- 105
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 5,564,315
- Address
- 12 Penns Trail, NEWTOWN, 18940
- Web
- https://www.onconova.com/
- Phone
- +1 2677593680
- Auditors
- Ernst & Young LLP
Upcoming Events for TRAW
Traws Pharma Inc Annual Shareholders Meeting
Q3 2025 Traws Pharma Inc Earnings Release
Similar to TRAW
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Traws Pharma share price?
As of Today at 23:46 UTC, shares in Traws Pharma are trading at $1.43. This share price information is delayed by 15 minutes.
How has the Traws Pharma share price performed this year?
Shares in Traws Pharma last closed at $1.43 and the price had moved by -87.29% over the past 365 days. In terms of relative price strength the Traws Pharma share price has underperformed the S&P500 Index by -88.76% over the past year.
What are the analyst and broker recommendations for Traws Pharma?
The overall consensus recommendation for Traws Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Traws Pharma dividend yield?
Traws Pharma does not currently pay a dividend.
Does Traws Pharma pay a dividend?
Traws Pharma does not currently pay a dividend.
When does Traws Pharma next pay dividends?
Traws Pharma does not currently pay a dividend.
How do I buy Traws Pharma shares?
To buy shares in Traws Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Traws Pharma?
As of the previous close price of $1.43, shares in Traws Pharma had a market capitalisation of $7.96m.
Where are Traws Pharma shares listed?
Here are the trading details for Traws Pharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: TRAW
What kind of share is Traws Pharma?
Based on an overall assessment of its quality, value and momentum Traws Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Traws Pharma share price forecast for 2025?
The analyst consensus target price for shares in Traws Pharma is $150.00. That is 10389.51% above the last closing price of $1.43.
Analysts covering Traws Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$35.52 for the next financial year.
Find out moreWhat is the trend in the Traws Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Traws Pharma. Over the past six months, its share price has underperformed the S&P500 Index by -89.8%.
As of the last closing price of $1.43, shares in Traws Pharma were trading -67.45% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Traws Pharma PE Ratio?
The Traws Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.43.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Traws Pharma?
Traws Pharma's management team is headed by:
- James Marino - NEC
- Steven Fruchtman - PRE
- Mark Guerin - CFO
- Abraham Oler - SVP
- Mark Gelder - OTH
- Jerome Groopman - IND
- Viren Mehta - IND
- M. Teresa Shoemaker - IND
- Jack Stover - IND